Olfson Mark, Marcus Steven C, Shaffer David
New York State Psychiatric Institute/Department of Psychiatry, College of Physicians and Surgeons of Columbia University, New York, NY 10032, USA.
Arch Gen Psychiatry. 2006 Aug;63(8):865-72. doi: 10.1001/archpsyc.63.8.865.
The Food and Drug Administration has issued a boxed warning concerning increased suicidal ideation and behavior associated with antidepressant drug treatment in children and adolescents. It is unknown whether antidepressant agents increase the risk of suicide death in children or adults.
To estimate the relative risk of suicide attempt and suicide death in severely depressed children and adults treated with antidepressant drugs vs those not treated with antidepressant drugs.
Matched case-control study.
Outpatient treatment settings in the United States.
Medicaid beneficiaries from all 50 states who received inpatient treatment for depression, excluding patients treated for pregnancy, bipolar disorder, schizophrenia or other psychoses, mental retardation, dementia, or delirium. Controls were matched to cases for age, sex, race or ethnicity, state of residence, substance use disorder, recent suicide attempt, number of days since hospital discharge, and recent treatment with antipsychotic, anxiolytic/hypnotic, mood stabilizer, and stimulant medications.
Suicide attempts and suicide deaths.
In adults (aged 19-64 years), antidepressant drug treatment was not significantly associated with suicide attempts (odds ratio [OR], 1.10; 95% confidence interval [CI], 0.86-1.39 [521 cases and 2394 controls]) or suicide deaths (OR, 0.90; 95% CI, 0.52-1.55 [86 cases and 396 controls]). However, in children and adolescents (aged 6-18 years), antidepressant drug treatment was significantly associated with suicide attempts (OR, 1.52; 95% CI, 1.12-2.07 [263 cases and 1241 controls]) and suicide deaths (OR, 15.62; 95% CI, 1.65-infinity [8 cases and 39 controls]).
In these high-risk patients, antidepressant drug treatment does not seem to be related to suicide attempts and death in adults but might be related in children and adolescents. These findings support careful clinical monitoring during antidepressant drug treatment of severely depressed young people.
美国食品药品监督管理局已发布黑框警告,提示儿童和青少年使用抗抑郁药物治疗会增加自杀观念和行为。目前尚不清楚抗抑郁药物是否会增加儿童或成人自杀死亡的风险。
评估接受抗抑郁药物治疗的重度抑郁儿童和成人与未接受抗抑郁药物治疗的患者相比,自杀未遂和自杀死亡的相对风险。
配对病例对照研究。
美国的门诊治疗机构。
来自美国50个州的医疗补助受益人中因抑郁症接受住院治疗的患者,排除因怀孕、双相情感障碍、精神分裂症或其他精神病、智力障碍、痴呆或谵妄而接受治疗的患者。对照在年龄、性别、种族或民族、居住州、物质使用障碍、近期自杀未遂、出院天数以及近期使用抗精神病药物、抗焦虑/催眠药物、心境稳定剂和兴奋剂药物治疗等方面与病例进行匹配。
自杀未遂和自杀死亡情况。
在成年人(19至64岁)中,抗抑郁药物治疗与自杀未遂(比值比[OR],1.10;95%置信区间[CI],0.86 - 1.39[521例病例和2394例对照])或自杀死亡(OR,0.90;95%CI,0.52 - 1.55[86例病例和396例对照])无显著相关性。然而,在儿童和青少年(6至18岁)中,抗抑郁药物治疗与自杀未遂(OR,1.52;95%CI,1.12 - 2.07[263例病例和1241例对照])和自杀死亡(OR,15.62;95%CI,1.65 - 无穷大[8例病例和39例对照])显著相关。
在这些高危患者中,抗抑郁药物治疗似乎与成年人的自杀未遂和死亡无关,但可能与儿童和青少年有关。这些发现支持在对重度抑郁的年轻人进行抗抑郁药物治疗期间进行仔细的临床监测。